ARTICLE | Product Development
J&J to bring Rybrevant into two Phase III colorectal cancer studies based on Phase II data
By Lauren Martz, Executive Director, Biopharma Intelligence
September 14, 2024 2:55 PM UTC
J&J’s Rybrevant is taking on another EGFR standard-of-care therapy in a new indication, with Phase II data that suggest the bispecific renders certain metastatic colorectal patients eligible for curative surgery. The data add more support to the case for targeting two oncogenic pathways with a single compound.
At the European Society of Medical Oncology (ESMO) conference, Johnson & Johnson (NYSE:JNJ) reported that Rybrevant amivantamab plus chemotherapy — either the mFOLFOX6 or FOLFIRI regimen — led to an objective resonse rate (ORR) of 49% as first- or second-line therapy for colorectal cancers lacking RAS or BRAF mutations in the Phase II OrigAMI-1 study…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653556/rybrevant-shows-colorectal-cancer-promise-in-latest-bispecifics-win